Browsing Cancer Therapeutics by author "Chesler, Louis"
Now showing items 21-40 of 43
-
Intrinsic susceptibility MRI identifies tumors with ALKF1174L mutation in genetically-engineered murine models of high-risk neuroblastoma.
Jamin, Y; Glass, L; Hallsworth, A; George, R; Koh, D-M; et al. (PUBLIC LIBRARY SCIENCE, 2014-03-25)The early identification of children presenting ALK(F1174L)-mutated neuroblastoma, which are associated with resistance to the promising ALK inhibitor crizotinib and a marked poorer prognosis, has become a clinical priority. ... -
Investigating the Contribution of Collagen to the Tumor Biomechanical Phenotype with Noninvasive Magnetic Resonance Elastography.
Li, J; Zormpas-Petridis, K; Boult, JKR; Reeves, EL; Heindl, A; et al. (AMER ASSOC CANCER RESEARCH, 2019-11-15)Increased stiffness in the extracellular matrix (ECM) contributes to tumor progression and metastasis. Therefore, stromal modulating therapies and accompanying biomarkers are being developed to target ECM stiffness. Magnetic ... -
Liquid biopsy for children with central nervous system tumours: Clinical integration and technical considerations.
Stankunaite, R; Marshall, LV; Carceller, F; Chesler, L; Hubank, M; et al. (FRONTIERS MEDIA SA, 2022-11-16)Circulating cell-free DNA (cfDNA) analysis has the potential to revolutionise the care of patients with cancer and is already moving towards standard of care in some adult malignancies. Evidence for the utility of cfDNA ... -
Lorlatinib with or without chemotherapy in ALK-driven refractory/relapsed neuroblastoma: phase 1 trial results.
Goldsmith, KC; Park, JR; Kayser, K; Malvar, J; Chi, Y-Y; et al. (NATURE PORTFOLIO, 2023-05-01)Neuroblastomas harbor ALK aberrations clinically resistant to crizotinib yet sensitive pre-clinically to the third-generation ALK inhibitor lorlatinib. We conducted a first-in-child study evaluating lorlatinib with and ... -
Macrophage-Derived IL1β and TNFα Regulate Arginine Metabolism in Neuroblastoma.
Fultang, L; Gamble, LD; Gneo, L; Berry, AM; Egan, SA; et al. (AMER ASSOC CANCER RESEARCH, 2019-02-01)Neuroblastoma is the most common childhood solid tumor, yet the prognosis for high-risk disease remains poor. We demonstrate here that arginase 2 (ARG2) drives neuroblastoma cell proliferation via regulation of arginine ... -
Molecular Characterization of Circulating Tumor DNA in Pediatric Rhabdomyosarcoma: A Feasibility Study.
Ruhen, O; Lak, NSM; Stutterheim, J; Danielli, SG; Chicard, M; et al. (LIPPINCOTT WILLIAMS & WILKINS, 2022-10-01)PURPOSE: Rhabdomyosarcomas (RMS) are rare neoplasms affecting children and young adults. Efforts to improve patient survival have been undermined by a lack of suitable disease markers. Plasma circulating tumor DNA (ctDNA) ... -
MRI Imaging of the Hemodynamic Vasculature of Neuroblastoma Predicts Response to Antiangiogenic Treatment.
Zormpas-Petridis, K; Jerome, NP; Blackledge, MD; Carceller, F; Poon, E; et al. (AMER ASSOC CANCER RESEARCH, 2019-06)Childhood neuroblastoma is a hypervascular tumor of neural origin, for which antiangiogenic drugs are currently being evaluated; however, predictive biomarkers of treatment response, crucial for successful delivery of ... -
Mutations in ALK signaling pathways conferring resistance to ALK inhibitor treatment lead to collateral vulnerabilities in neuroblastoma cells.
Berlak, M; Tucker, E; Dorel, M; Winkler, A; McGearey, A; et al. (BMC, 2022-06-10)BACKGROUND: Development of resistance to targeted therapies has tempered initial optimism that precision oncology would improve poor outcomes for cancer patients. Resistance mechanisms, however, can also confer new ... -
MYCN expression induces replication stress and sensitivity to PARP inhibition in neuroblastoma.
King, D; Li, XD; Almeida, GS; Kwok, C; Gravells, P; et al. (Impact Journals, LLC, 2020-06-09)This study investigates the influence expression of the MYCN oncogene has on the DNA damage response, replication fork progression and sensitivity to PARP inhibition in neuroblastoma. In a panel of neuroblastoma cell lines, ... -
Neuroblastoma Arginase Activity Creates an Immunosuppressive Microenvironment That Impairs Autologous and Engineered Immunity.
Mussai, F; Egan, S; Hunter, S; Webber, H; Fisher, J; et al. (AMER ASSOC CANCER RESEARCH, 2015-08-01)Neuroblastoma is the most common extracranial solid tumor of childhood, and survival remains poor for patients with advanced disease. Novel immune therapies are currently in development, but clinical outcomes have not ... -
Noninvasive MRI Native T1 Mapping Detects Response to MYCN-targeted Therapies in the Th-MYCN Model of Neuroblastoma.
Zormpas-Petridis, K; Poon, E; Clarke, M; Jerome, NP; Boult, JKR; et al. (AMER ASSOC CANCER RESEARCH, 2020-08-15)Noninvasive early indicators of treatment response are crucial to the successful delivery of precision medicine in children with cancer. Neuroblastoma is a common solid tumor of young children that arises from anomalies ... -
Novel therapeutic strategies targeting telomere maintenance mechanisms in high-risk neuroblastoma.
George, SL; Parmar, V; Lorenzi, F; Marshall, LV; Jamin, Y; et al. (BMC, 2020-05-06)The majority of high-risk neuroblastomas can be divided into three distinct molecular subgroups defined by the presence of MYCN amplification, upstream TERT rearrangements or alternative lengthening of telomeres (ALT). The ... -
Orally bioavailable CDK9/2 inhibitor shows mechanism-based therapeutic potential in MYCN-driven neuroblastoma.
Poon, E; Liang, T; Jamin, Y; Walz, S; Kwok, C; et al. (AMER SOC CLINICAL INVESTIGATION INC, 2020-11-02)The undruggable nature of oncogenic Myc transcription factors poses a therapeutic challenge in neuroblastoma, a pediatric cancer in which MYCN amplification is strongly associated with unfavorable outcome. Here, we show ... -
p53 Loss in MYC-Driven Neuroblastoma Leads to Metabolic Adaptations Supporting Radioresistance.
Yogev, O; Barker, K; Sikka, A; Almeida, GS; Hallsworth, A; et al. (AMER ASSOC CANCER RESEARCH, 2016-09-29)Neuroblastoma is the most common childhood extracranial solid tumor. In high-risk cases, many of which are characterized by amplification of MYCN, outcome remains poor. Mutations in the p53 (TP53) tumor suppressor are rare ... -
Pre-clinical imaging of transgenic mouse models of neuroblastoma using a dedicated 3-element solenoid coil on a clinical 3T platform.
Almeida, GS; Panek, R; Hallsworth, A; Webber, H; Papaevangelou, E; et al. (NATURE PUBLISHING GROUP, 2017-09-05)BACKGROUND: The use of clinical MRI scanners to conduct pre-clinical research facilitates comparisons with clinical studies. Here the utility and sensitivity of anatomical and functional MRI data/biomarkers acquired from ... -
Preclinical transgenic and patient-derived xenograft models recapitulate the radiological features of human adamantinomatous craniopharyngioma.
Boult, JKR; Apps, JR; Hölsken, A; Hutchinson, JC; Carreno, G; et al. (WILEY, 2018-07-01)To assess the clinical relevance of transgenic and patient-derived xenograft models of adamantinomatous craniopharyngioma (ACP) using serial magnetic resonance imaging (MRI) and high resolution post-mortem microcomputed ... -
SHH pathway inhibition is protumourigenic in adamantinomatous craniopharyngioma.
Carreno, G; Boult, JKR; Apps, J; Gonzalez-Meljem, JM; Haston, S; et al. (BIOSCIENTIFICA LTD, 2019-03-01)Pharmacological inhibition of the sonic hedgehog (SHH) pathway can be beneficial against certain cancers but detrimental in others. Adamantinomatous craniopharyngioma (ACP) is a relevant pituitary tumour, affecting children ... -
Structural basis of N-Myc binding by Aurora-A and its destabilization by kinase inhibitors.
Richards, MW; Burgess, SG; Poon, E; Carstensen, A; Eilers, M; et al. (NATL ACAD SCIENCES, 2016-11-29)Myc family proteins promote cancer by inducing widespread changes in gene expression. Their rapid turnover by the ubiquitin-proteasome pathway is regulated through phosphorylation of Myc Box I and ubiquitination by the E3 ... -
Subclonal reconstruction of tumors by using machine learning and population genetics.
Caravagna, G; Heide, T; Williams, MJ; Zapata, L; Nichol, D; et al. (NATURE PUBLISHING GROUP, 2020-09-01)Most cancer genomic data are generated from bulk samples composed of mixtures of cancer subpopulations, as well as normal cells. Subclonal reconstruction methods based on machine learning aim to separate those subpopulations ... -
Systemic oncolytic adenovirus delivered in mesenchymal carrier cells modulate tumor infiltrating immune cells and tumor microenvironment in mice with neuroblastoma.
Franco-Luzón, L; González-Murillo, Á; Alcántara-Sánchez, C; García-García, L; Tabasi, M; et al. (Impact Journals, LLC, 2020-01-28)Celyvir (autologous mesenchymal cells -MSCs- that carry an oncolytic adenovirus) is a new therapeutic strategy for metastatic tumors developed by our research group over the last decade. There are limitations for studying ...